サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1392710

高リン血症治療の世界市場レポート 2024年

Hyperphosphatemia Treatment Global Market Report 2024
出版日: 受注後更新 | 発行: The Business Research Company | ページ情報: 英文 200 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.58円
高リン血症治療の世界市場レポート 2024年
出版日: 受注後更新
発行: The Business Research Company
ページ情報: 英文 200 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 目次
概要

高リン血症治療の市場規模は近年急速に拡大しています。2023年の41億米ドルから2024年には46億1,000万米ドルに、CAGR12.6％で拡大します。過去の期間中の成長は、慢性腎臓病（CKD）の罹患率の増加、高齢化人口の増加、糖尿病と高血圧の高い有病率、透析患者人口の拡大、医学研究と高リン血症の診断の進歩などの要因によるものと考えられます。

高リン血症治療市場規模は、今後数年間で急成長が見込まれます。2028年にはCAGR13.1％で75億4,000万米ドルに成長します。予測期間中に予想される成長は、高リン血症の原因となる生活習慣病の増加、高齢化人口の継続的な増加、高リン血症に対する認識と診断の高まり、疾病負担の大きい新興市場の拡大、新興国におけるカルシウム系リン酸結合剤の処方シェアの増加といった要因に起因すると考えられます。予測期間中に予想される注目すべき動向としては、高リン血症治療技術の進歩、遠隔医療と遠隔患者モニタリングの統合、研究開発のための共同研究および提携、高リン血症における患者教育と生活習慣管理の重視、新規リン酸塩結合剤および治療法の開発などが挙げられます。

2023年の高リン血症治療市場で最大の地域は北米でした。アジア太平洋は予測期間中に最も急成長する地域と予想されます。高リン血症治療市場レポートの対象地域は、アジア太平洋、西欧、東欧、北米、南米、中東・アフリカです。

目次

第1章 エグゼクティブサマリー

第2章 高リン血症治療市場の特徴

第3章 高リン血症治療市場の動向と戦略

第4章 高リン血症治療市場- マクロ経済シナリオ

  • 高インフレが市場に与える影響
  • ウクライナ・ロシア戦争が市場に与える影響
  • COVID-19による市場への影響

第5章 世界の高リン血症治療市場規模と成長

  • 市場促進要因・市場抑制要因
    • 市場促進要因
    • 市場抑制要因
  • 市場規模と成長実績、2018～2023年
  • 市場規模と成長予測、2023～2028年、2033F

第6章 高リン血症治療市場セグメンテーション

  • 世界の高リン血症治療市場、製品別セグメンテーション、実績および予測、2018-2023、2023-2028F、2033F
  • セベラマー
  • カルシウムベースのリン酸塩結合剤
  • 鉄ベースのリン酸塩バインダー
  • 炭酸ランタン
  • その他の製品
  • 世界の高リン血症治療市場、流通チャネル別セグメンテーション、実績および予測、2018-2023、2023-2028F、2033F
  • 病院薬局
  • 小売薬局
  • オンラインストア

第7章 高リン血症治療市場の地域および国分析

  • 世界の高リン血症治療市場、地域別、実績および予測、2018年から2023年、2023年から2028年まで、2033年まで
  • 世界の高リン血症治療市場、国別、実績および予測、2018年から2023年、2023年から2028年まで、2033年まで

第8章 アジア太平洋の高リン血症治療市場

  • 概要
  • 地域情報、COVID-19の影響、市場情報、背景情報、政府の取り組み、規制、規制機関、主要団体、課税額、法人税構造、投資、主要企業
  • 製品別セグメンテーション、実績および予測、2018-2023、2023-2028F、2033F
  • 流通チャネル別のセグメンテーション、実績および予測、2018-2023、2023-2028F、2033F

第9章 中国の高リン血症治療市場

第10章 インドの高リン血症治療市場

第11章 日本の高リン血症治療市場

第12章 オーストラリアの高リン血症治療市場

第13章 インドネシアの高リン血症治療市場

第14章 韓国の高リン血症治療市場

第15章 西欧の高リン血症治療市場

  • 概要
  • 製品別セグメンテーション、実績および予測、2018-2023、2023-2028F、2033F
  • 流通チャネル別のセグメンテーション、実績および予測、2018-2023、2023-2028F、2033F

第16章 英国の高リン血症治療市場

第17章 ドイツの高リン血症治療市場

第18章 フランスの高リン血症治療市場

第19章 イタリアの高リン血症治療市場

第20章 スペインの高リン血症治療市場

第21章 東欧の高リン血症治療市場

  • 概要
  • 製品別セグメンテーション、実績および予測、2018-2023、2023-2028F、2033F
  • 流通チャネル別のセグメンテーション、実績および予測、2018-2023、2023-2028F、2033F

第22章 ロシアの高リン血症治療市場

第23章 北米の高リン血症治療市場

  • 概要
  • 製品別のセグメンテーション、実績および予測、2018-2023、2023-2028F、2033F
  • 流通チャネル別のセグメンテーション、実績および予測、2018-2023、2023-2028F、2033F

第24章 米国の高リン血症治療市場

第25章 カナダの高リン血症治療市場

第26章 南米の高リン血症治療市場

  • 概要
  • 製品別セグメンテーション、実績および予測、2018-2023、2023-2028F、2033F
  • 流通チャネル別のセグメンテーション、実績および予測、2018-2023、2023-2028F、2033F

第27章 ブラジルの高リン血症治療市場

第28章 中東の高リン血症治療市場

  • 概要
  • 製品別セグメンテーション、実績および予測、2018-2023、2023-2028F、2033F
  • 流通チャネル別のセグメンテーション、実績および予測、2018-2023、2023-2028F、2033F

第29章 アフリカの高リン血症治療市場

  • 概要
  • 製品別セグメンテーション、実績および予測、2018-2023、2023-2028F、2033F
  • 流通チャネル別のセグメンテーション、実績および予測、2018-2023、2023-2028F、2033F

第30章 高リン血症治療市場の競合情勢と企業プロファイル

  • 高リン血症治療市場の競合情勢
  • 高リン血症治療市場の企業プロファイル
    • Sanofi SA
    • Akebia Therapeutics Inc.
    • AMAG Pharmaceuticals Inc.
    • Ardelyx Inc.
    • Astellas Pharma Inc.

第31章 世界の高リン血症治療市場の競合ベンチマーキング

第32章 世界の高リン血症治療市場の競合ダッシュボード

第33章 高リン血症治療市場における主要な合併と買収

第34章 高リン血症治療市場の将来展望と可能性分析

第35章 付録

目次
Product Code: r10398

“Hyperphosphatemia Treatment Global Market Report 2024 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on hyperphosphatemia treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for hyperphosphatemia treatment? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The hyperphosphatemia treatment market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

  • 1) By Product: Sevelamer; Calcium-Based Phosphate Binders; Iron-Based Phosphate Binders; Lanthanum Carbonate; Other products
  • 2) By Distribution channel: Hospital Pharmacy; Retail Pharmacy; Online stores
  • Companies Mentioned: Sanofi SA; Akebia Therapeutics Inc.; AMAG Pharmaceuticals Inc.; Ardelyx Inc.; Astellas Pharma Inc.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Hyperphosphatemia treatment involves a class of drugs designed to enhance renal excretion for managing patients with elevated levels of phosphates. The most effective method is through volume replenishment using saline and forced diuresis with a loop diuretic such as furosemide or bumetanide.

The primary products in the hyperphosphatemia treatment market include sevelamer, calcium-based phosphate binders, iron-based phosphate binders, lanthanum carbonate, and others. The sevelamer market comprises sales of sevelamer products by entities (organizations, partnerships, and sole traders). Sevelamer is a phosphate-binding medication used to treat hyperphosphatemia in patients with chronic kidney diseases. The distribution of hyperphosphatemia treatment occurs through various channels, including hospital pharmacies, retail pharmacies, and online stores. In terms of dosage form, it is segmented into capsules, tablets, and syrups.

The hyperphosphatemia treatment market research report is one of a series of new reports from The Business Research Company that provides hyperphosphatemia treatment market statistics, including hyperphosphatemia treatment industry global market size, regional shares, competitors with a hyperphosphatemia treatment market share, detailed hyperphosphatemia treatment market segments, market trends and opportunities, and any further data you may need to thrive in the hyperphosphatemia treatment industry. This hyperphosphatemia treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The hyperphosphatemia treatment market size has grown rapidly in recent years. It will grow from $4. 1 billion in 2023 to $4. 61 billion in 2024 at a compound annual growth rate (CAGR) of 12. 6%. The growth during the historical period can be attributed to factors such as an increased incidence of chronic kidney disease (CKD), the growth of the aging population, a high prevalence of diabetes and hypertension, the expansion of the dialysis patient population, and advances in medical research and the diagnosis of hyperphosphatemia.

The hyperphosphatemia treatment market size is expected to see rapid growth in the next few years. It will grow to $7. 54 billion in 2028 at a compound annual growth rate (CAGR) of 13. 1%. The anticipated growth in the forecast period can be attributed to factors such as the rise in lifestyle-related diseases contributing to hyperphosphatemia, continued growth in aging demographics, increasing awareness and diagnosis of hyperphosphatemia, expansion of emerging markets with a high disease burden, and a higher prescription share of calcium-based phosphate binders in emerging countries. Noteworthy trends expected in the forecast period encompass advancements in hyperphosphatemia treatment technologies, the integration of telehealth and remote patient monitoring, collaborations and partnerships for research and development, a focus on patient education and lifestyle management in hyperphosphatemia, and the development of novel phosphate binders and therapies.

The growth of the hyperphosphatemia treatment market is being fueled by the increasing prevalence of chronic diseases among patients, which require long-term care. Chronic diseases, including cardiovascular diseases, chronic kidney disease, chronic respiratory conditions, hyperparathyroidism, diabetes, and cancer, contribute to a significant portion of global deaths, with 74% attributed to non-communicable diseases (NCDs) or chronic diseases, as reported by the World Health Organization in September 2023. Notably, kidney diseases are on the rise, with untreated kidney failure claiming the lives of approximately 1 million individuals each year, according to SingleCare Services LLC in February 2023. The escalating cases of hyperphosphatemia in patients with end-stage renal disease (ESRD) are driving the demand for hyperphosphatemia treatment drugs.

The hyperphosphatemia treatment market is anticipated to experience growth due to the increasing adoption of dietary modifications. Intentional changes in eating habits or diet adjustments play a significant role in managing hyperphosphatemia, offering control over phosphate levels, preventing complications, reducing the need for medication, promoting overall health, and enhancing the quality of life. For example, in June 2022, the Food Standards Agency (FSA) in the UK reported that eight out of ten people have made changes to their eating habits over the past 12 months. The survey revealed that 23% of Scottish adults acknowledged their diet had worsened during the epidemic, and 75% recognized the need for significant dietary adjustments to improve their health. Thus, the increasing trend of dietary modifications is a driving force for the hyperphosphatemia treatment market.

A key trend in the hyperphosphatemia treatment market is the surge in research and development activities. Companies in this sector are intensively focused on R&D to develop innovative therapies for renal diseases and associated chronic conditions. For instance, in May 2021, Shanghai-based biopharmaceutical company Alebund Pharmaceuticals secured $60 million in a Series B funding round, aimed at accelerating the development of innovative drugs and solutions for renal diseases, including hyperphosphatemia.

Major companies in the hyperphosphatemia treatment market are concentrating on the development of innovative products, such as Xphozah, to drive market revenues. Xphozah, designed to treat hyperphosphatemia, addresses the excessive phosphorus causing calcium removal from bones and various body parts. In October 2023, Ardelyx Inc., a US-based biopharmaceutical company, received FDA approval for Xphozah. This approval is for the treatment of hyperphosphatemia in patients unresponsive or intolerant to current standard-of-care phosphate binder therapies.

In May 2023, South Africa-based healthcare services group Life Healthcare Group Holdings Limited acquired Fresenius Medical Care AG and Co. KGaA for an undisclosed amount. This strategic acquisition enhances Life Healthcare's offerings in acute and ongoing renal dialysis treatments in South Africa. With the acquisition, Life Healthcare aims to play a vital role in ensuring the continuity of existing patient care plans. Fresenius Medical Care AG and Co. KGaA, a Germany-based company manufacturing hyperphosphatemia treatment drugs, is now part of Life Healthcare Group Holdings Limited.

Major companies operating in the in the hyperphosphatemia treatment market report are Sanofi SA, Akebia Therapeutics Inc., AMAG Pharmaceuticals Inc., Ardelyx Inc., Astellas Pharma Inc., Fresenius Medical Care AG & Co. KGaA, Keryx Biopharmaceuticals Inc., Lupin Limited, Shire plc, Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Ultragenyx Pharmaceutical Inc., Unicycive Therapeutics Inc., Vifor Pharma Management Ltd., Zeria Pharmaceutical Co. Ltd., Abbott Laboratories, Amgen Inc., AstraZeneca plc, B. Braun Melsungen AG, Baxter International Inc., Beckman Coulter Inc., Cleveland Clinic, DaVita Inc., Encompass Health Corporation, FMC Corporation, Hospital Corporation of America Healthcare Inc., Kyowa Kirin Pharmaceuticals Co. Ltd., Mayo Clinic, Medtronic plc, OPKO Health Inc., Roche Diagnostics Corporation, Siemens Healthineers AG, Sysmex Corporation, Tenet Healthcare Corporation, Thermo Fisher Scientific Inc., UnitedHealth Group Inc.

North America was the largest region in the hyperphosphatemia treatment market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hyperphosphatemia treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the hyperphosphatemia treatment market report are: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain.

The hyperphosphatemia treatment market includes revenues earned by lowering the phosphate load and maintaining serum phosphorus levels within the normal range. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified)).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Table of Contents

1. Executive Summary

2. Hyperphosphatemia Treatment Market Characteristics

3. Hyperphosphatemia Treatment Market Trends And Strategies

4. Hyperphosphatemia Treatment Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On The Market
  • 4.2. Ukraine-Russia War Impact On The Market
  • 4.3. COVID-19 Impact On The Market

5. Global Hyperphosphatemia Treatment Market Size and Growth

  • 5.1. Global Hyperphosphatemia Treatment Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Hyperphosphatemia Treatment Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Hyperphosphatemia Treatment Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Hyperphosphatemia Treatment Market Segmentation

  • 6.1. Global Hyperphosphatemia Treatment Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Sevelamer
  • Calcium-Based Phosphate Binders
  • Iron-Based Phosphate Binders
  • Lanthanum Carbonate
  • Other products
  • 6.2. Global Hyperphosphatemia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online stores

7. Hyperphosphatemia Treatment Market Regional And Country Analysis

  • 7.1. Global Hyperphosphatemia Treatment Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Hyperphosphatemia Treatment Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Hyperphosphatemia Treatment Market

  • 8.1. Asia-Pacific Hyperphosphatemia Treatment Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Hyperphosphatemia Treatment Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Hyperphosphatemia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Hyperphosphatemia Treatment Market

  • 9.1. China Hyperphosphatemia Treatment Market Overview
  • 9.2. China Hyperphosphatemia Treatment Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Hyperphosphatemia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Hyperphosphatemia Treatment Market

  • 10.1. India Hyperphosphatemia Treatment Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Hyperphosphatemia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Hyperphosphatemia Treatment Market

  • 11.1. Japan Hyperphosphatemia Treatment Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.2. Japan Hyperphosphatemia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Hyperphosphatemia Treatment Market

  • 12.1. Australia Hyperphosphatemia Treatment Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Hyperphosphatemia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Hyperphosphatemia Treatment Market

  • 13.1. Indonesia Hyperphosphatemia Treatment Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Hyperphosphatemia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Hyperphosphatemia Treatment Market

  • 14.1. South Korea Hyperphosphatemia Treatment Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.2. South Korea Hyperphosphatemia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Hyperphosphatemia Treatment Market

  • 15.1. Western Europe Hyperphosphatemia Treatment Market Overview
  • 15.2. Western Europe Hyperphosphatemia Treatment Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Hyperphosphatemia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Hyperphosphatemia Treatment Market

  • 16.1. UK Hyperphosphatemia Treatment Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Hyperphosphatemia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Hyperphosphatemia Treatment Market

  • 17.1. Germany Hyperphosphatemia Treatment Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Hyperphosphatemia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Hyperphosphatemia Treatment Market

  • 18. 1. France Hyperphosphatemia Treatment Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18. 2. France Hyperphosphatemia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Hyperphosphatemia Treatment Market

  • 19. 1. Italy Hyperphosphatemia Treatment Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19. 2. Italy Hyperphosphatemia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Hyperphosphatemia Treatment Market

  • 20.1. Spain Hyperphosphatemia Treatment Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain Hyperphosphatemia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Hyperphosphatemia Treatment Market

  • 21.1. Eastern Europe Hyperphosphatemia Treatment Market Overview
  • 21.2. Eastern Europe Hyperphosphatemia Treatment Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Hyperphosphatemia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Hyperphosphatemia Treatment Market

  • 22.1. Russia Hyperphosphatemia Treatment Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Hyperphosphatemia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Hyperphosphatemia Treatment Market

  • 23.1. North America Hyperphosphatemia Treatment Market Overview
  • 23.2. North America Hyperphosphatemia Treatment Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Hyperphosphatemia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Hyperphosphatemia Treatment Market

  • 24.1. USA Hyperphosphatemia Treatment Market Overview
  • 24.2. USA Hyperphosphatemia Treatment Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Hyperphosphatemia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Hyperphosphatemia Treatment Market

  • 25.1. Canada Hyperphosphatemia Treatment Market Overview
  • 25.2. Canada Hyperphosphatemia Treatment Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Hyperphosphatemia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Hyperphosphatemia Treatment Market

  • 26.1. South America Hyperphosphatemia Treatment Market Overview
  • 26.2. South America Hyperphosphatemia Treatment Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Hyperphosphatemia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Hyperphosphatemia Treatment Market

  • 27.1. Brazil Hyperphosphatemia Treatment Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Hyperphosphatemia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Hyperphosphatemia Treatment Market

  • 28.1. Middle East Hyperphosphatemia Treatment Market Overview
  • 28.2. Middle East Hyperphosphatemia Treatment Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Hyperphosphatemia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Hyperphosphatemia Treatment Market

  • 29.1. Africa Hyperphosphatemia Treatment Market Overview
  • 29.2. Africa Hyperphosphatemia Treatment Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Hyperphosphatemia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Hyperphosphatemia Treatment Market Competitive Landscape And Company Profiles

  • 30.1. Hyperphosphatemia Treatment Market Competitive Landscape
  • 30.2. Hyperphosphatemia Treatment Market Company Profiles
    • 30.2.1. Sanofi SA
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1. 4. Financial Performance
    • 30.2.2. Akebia Therapeutics Inc.
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2. 4. Financial Performance
    • 30.2.3. AMAG Pharmaceuticals Inc.
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3. 4. Financial Performance
    • 30.2. 4. Ardelyx Inc.
      • 30.2. 4.1. Overview
      • 30.2. 4.2. Products and Services
      • 30.2. 4.3. Strategy
      • 30.2. 4. 4. Financial Performance
    • 30.2. 5. Astellas Pharma Inc.
      • 30.2. 5.1. Overview
      • 30.2. 5.2. Products and Services
      • 30.2. 5.3. Strategy
      • 30.2. 5. 4. Financial Performance

31. Global Hyperphosphatemia Treatment Market Competitive Benchmarking

32. Global Hyperphosphatemia Treatment Market Competitive Dashboard

33. Key Mergers And Acquisitions In The Hyperphosphatemia Treatment Market

34. Hyperphosphatemia Treatment Market Future Outlook and Potential Analysis

  • 34.1 Hyperphosphatemia Treatment Market In 2028 - Countries Offering Most New Opportunities
  • 34.2 Hyperphosphatemia Treatment Market In 2028 - Segments Offering Most New Opportunities
  • 34. 3 Hyperphosphatemia Treatment Market In 2028 - Growth Strategies
    • 34.3.1 Market Trend Based Strategies
    • 34.3.2 Competitor Strategies

35. Appendix

  • 35.1. Abbreviations
  • 35.2. Currencies
  • 35.3. Historic And Forecast Inflation Rates
  • 35. 4. Research Inquiries
  • 35. 5. The Business Research Company
  • 35. 6. Copyright And Disclaimer